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Abstract:  Toxicity assessment of nanoparticles, now widespread in our environment, is an important issue.  We have
focused attention on the carcinogenic potential of copper oxide (CuO) and titanium dioxide (TiO2).  In experiment 1, a
sequential pilot study, the effectiveness of a carcinogenic bioassay featuring intraperitoneal injection (i.p.) of 20 mg 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) or 0.1 % N-bis(2-hydroxypropyl)nitrosamine (DHPN) in drinking
water for 2 weeks was examined.  Based on the results, DHPN, as the lung carcinogen, and evaluation at week 30 were
selected as the most appropriate for our purposes in Experiment 1.  In experiment 2, the carcinogenic bioassay was used
to assess the carcinogenic potentials of instilled nanoparticles of CuO and TiO2.  There were no significant intergroup
differences in the lung neoplastic lesions induced by DHPN, although the neoplastic lesions induced by the nanoparticles
in the CuO or TiO2 intratracheal instillation (i.t.) groups, demonstrated a tendency to increase compared with the
microparticles administration.  At the very least, the carcinogenic bioassay with DHPN proved useful for assessment of
the modifying effects of instilled particles, and further assessment of the carcinogenic potential of nanoparticles appears
warranted.   (J Toxicol Pathol 2009; 22: 71–78)
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Introduction
The health risk posed by fine particles, especially
nanoparticles in the air, has attracted much greater attention
with the development of nanotechnology.  The nanoparticle
is a source of air pollution1, but there are very few
established evaluation methods for detection of lung
carcinogenicity. 
We have previously described a rat in vivo bioassay for
detection of hazards due to fine particles by intratracheal
instillation (i.t.)2, which can be used for risk assessment, at
an early stage, posed by materials inhaled into deep lung
tissue.  Sequential analysis of the effects of quartz (DQ-12, 4
mg/rat), a typical lung toxic agent3, revealed days 1 and 28
after instillation to be most appropriate for detection of acute
and subacute inflammatory changes, respectively.  For
further validation, the toxicity of fine particles from various
materials (quartz, hydrotalcite, potassium octatitanate,
palladium oxide and carbon black) was examined in our in
vivo bioassay4; 16 particle types, including nanoparticles
were also examined5.  With the same volume of particles, 2
mg/rat i.t., the nanoparticles of both CuO and NiO caused
much more severe acute toxicity, such as acute death and
severe inflammatory changes in neutrophil infiltration and
edema, than micrometer-diameter particles of the same
materials.  These experiments confirmed the suitability of
this bioassay for fine particle toxicity assessment.  However,
it cannot predict carcinogenicity.
We therefore aimed to establish a bioassay using the
tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) as an initiating carcinogen.  In
the lungs of A/J female mice, the initial event in this model
is reported to be formation of O6-methylguanine-DNA, a
major promutagenic adduct that leads to GC>AT transitional
mispairing and subsequent activation of the K-ras proto-
oncogene6,7.  The bioassay model of NNK inducing lung
tumor using A/J mice is used extensively, and we have
previously reported the inhibitory effects of 8-
methoxypsoralen, a potent human CYP2A6 inhibitor8,9.  For
carcinogenic assessment of fine particles by i.t., however,
rats are more suitable because their tracheas are thick enough
to allow instillation.  There have been a number of reports of
NNK-induced bioassay models using rats10,11, and in the
present study, experiment 1, a pilot study, was conducted to
investigate the effectiveness of NNK for a carcinogenic
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bioassay model using F344 rats.  For comparison, N-bis(2-
hydroxypropyl)nitrosamine (DHPN), a carcinogen targeting
the lung, nasal cavity, paranasal cavity, liver, thyroid gland,
kidney, esophagus, colon and urinary bladder12–14, was
applied.  Quartz was employed as a typical lung toxic agent
to assess the influence of its inflammatory effects on lung
tumor development.
In experiment 2, the bioassay model with DHPN
assessed in experiment 1 was used to assess the carcinogenic
potentials of nanoparticles of copper oxide (CuO) and
titanium dioxide (TiO2) in comparison with the same
materials of micrometer order size.
Materials and Methods
Chemicals
NNK (Toronto Research Chemicals, Toronto, ON,
Canada) and DHPN (Nacalai Tesque Inc., Kyoto, Japan)
were employed for initiation.  Quartz dust (DQ-12) was
obtained from Deutsche Montan Technologie (GmbH,
Germany) with a particle diameter of less than 7 μm.
Titanium dioxide with a particle diameter of less than 5 μm
(Rutile form, Lot. TCG4139) (TiO2 micro) and titanium
dioxide with a particle diameter of 80 nm (Lot. DPN0960)
(TiO2 nano) were purchased from Wako Pure Chemical
Industries, Ltd. (Osaka, Japan).  Copper oxide with a particle
diameter of less than 5 μm (CAS1317-38-0; CuO micro) and
copper oxide with a particle diameter of 33 nm (CAS1317-
38-0; CuO nano) were purchased from Sigma-Aldrich (St.
Louis, MO, USA).  The particles were all suspended in
saline (Otsuka Isotonic sodium chloride solution, Otsuka
Pharmaceutical Factory, Inc., Tokushima, Japan). 
Animal treatment
Male F344/DuCrlCrj rats (4 weeks of age) purchased
from Japan Charles River (Kanagawa, Japan) were
maintained in the Kagawa University Animal Facility
according to the Institutional Regulations for Animal
Experiments.  The protocols of the experiments were
approved by the Animal Care and Use Committee.  The
animals were housed in polycarbonate cages with white
wood chips for bedding and given free access to drinking
water and a basal diet, CE-2 (CLEA Japan Inc., Tokyo,
Japan), under controlled conditions of humidity (60 ± 10%),
lighting (12-h light/dark cycle) and temperature (24 ± 2°C).
The experiments were started after a 2-week acclimation
period.
Experiment 1: The experimental design is shown in Fig.
1.  A total of 140, 6-week-old, male F344 rats were randomly
separated into 7 groups of 20 rats each.  At the start of the
experiment, groups 2 and 3 were administered a single
intraperitoneal injection (IP) of 20 mg NNK suspended in 1
ml saline, groups 4 and 5 received 3 IPs of 10 mg NNK
suspended in 1 ml saline in weeks 0, 1 and 2 and groups 6
and 7 were administered 0.1% DHPN in drinking water for 2
weeks.  In week 4, groups 1, 3, 5 and 7 were exposed by i.t.
to 0.5 mg quartz suspended in saline (0.2 ml) using an
aerosolizer (PennCentury Philadelphia, PA, USA), and
groups 4 and 6 were exposed by i.t. to 0.2 ml saline as
vehicle control groups.  The test solutions were sonicated to
maintain as much suspension as possible and 0.2 ml
solutions were instilled into each rate with 1 ml of air so that
the solution would be spread throughout in the lung.
Subgroups of 5 rats each were sacrificed in weeks 12, 16, 23
Fig. 2. Design of experiment 2.  A total of 120 rats (6-week-old) were
employed.  Groups 1–6: 0.1% DHPN in drinking water for 2
weeks.  Groups 1–5 and 7–11: i.t. of 0.5 mg/rat quartz (groups
1 and 7), CuO micro (groups 2 and 8), CuO nano (groups 3
and 9), TiO2 micro (groups 4 and 10) and TiO2 nano (groups 5
and 11) in week 4.  Group 6 was a DHPN control group, and
Group 12 was an untreated control group.  All rats were
sacrificed (S) at week 30.
Fig. 1. Design of experiment 1.  A total of 140, 6-week-old, male
F344 rats were employed.  Groups 2 and 3: a single IP of 20
mg NNK/1 ml saline.  Groups 3 and 4: 3 × IP of 10 mg NNK/
1 ml saline at weeks 0, 1 and 2.  Groups 6 and 7: 0.1% DHPN
in drinking water for 2 weeks.  At week 4, groups 1, 3, 5 and
7 received i.t. of 0.5 mg quartz (DQ-12)/0.2 ml saline (Q-i.t.),
and groups 4 and 6 received 0.2 ml of saline (S-i.t.).
Subgroups of 5 rats each were sacrificed (S) at weeks 12, 16,
23 and 30 thereafter.Yokohira, Hashimoto, Yamakawa et al. 73
and 30 thereafter. 
Experiment 2: The experimental design is shown in Fig.
2.  A total of 120 rats (6-week-old) were randomly separated
into 6 groups of 15 animals and an additional 6 groups of 5
animals each.  Groups 1-6 were administered 0.1% DHPN in
drinking water for 2 weeks.  Groups 1–5 and 7–11 were
exposed by i.t. to 0.5 mg/rat quartz (groups 1 and 7), CuO
micro (groups 2 and 8), CuO nano (groups 3 and 9), TiO2
micro (groups 4 and 10) and TiO2 nano (groups 5 and 11) in
saline (0.2 ml) using an aerosolizer in week 4.  Group 6 was
a DHPN control group, and Group 12 was an untreated
control group.  All rats were sacrificed in week 30. 
At autopsy, the lungs, liver and kidneys were removed.
The lungs, including the trachea and heart, were weighed,
infused with 10% phosphate buffered formalin and then
rinsed in 10% phosphate buffered formalin.  The weights of
the lungs were calculated by subtraction of the weight of the
remaining trachea and heart.  The organs were immersed in
10% phosphate buffered formalin for a week, and slices were
routinely processed for embedding in paraffin for
histopathological examination of H and E stained sections.
The histopathological specimens were routinely 2 slices of
the left lobe and 1 slice each of the other lobes. 
Histopathological analysis
Lung lesions were categorized as hyperplasia, adenoma
and adenocarcinoma in accordance with the established
criteria15.  Incidences were assessed along with numbers of
hyperplasias, adenomas and adenocarcinomas in experiment
1.  In experiment 2, in addition to the numbers, the areas of
adenomas and adenocarcinomas were assessed using an
Image Processor for Analytical Pathology (IPAP-WIN,
Sumika Technoservice Corporation, Osaka, Japan)16.  The
numbers and areas in experiment 2 were indicated as: No.
per 1 cm2, which was calculated as (number of lesions / total
area cm2 of lung per a slide), and % Area, which was
calculated as (total area of lesions / total area of lung per a
slide) ×100. 
Statistics
Body and organ weights and numbers and areas of the
induced lung lesions were analyzed by the Tukey-Kramer




After intratracheal instillation, no symptoms of dyspnea
were observed.  The general conditions of the rats in all the
groups did not change remarkably during the experimental
period. 
The average body weight of group 7 (DHPN and quartz
i.t. group), 337.4 ± 19.6 (g), was greater than that of group 5
Table 1. Number of Lesions in Lung Tissues Sections at Different Time Points (Experiment 1)
Weeks
Groups Treatment No.* Lesions 12 16 23 30
Group 1 Saline i.p. Hyperplasia 0.0 4.4 ± 1.1 0.0 0.4 ± 0.5
+ 20 Adenoma 0.0 0.0 0.0 0.0
Quartz i.t. Adenocarcinoma 0.0 0.0 0.0 0.0
Group 2 20 mg NNK i.p. Hyperplasia 0.8 ± 1.3 2.0 ± 2.9 0.6 ± 0.9 0.0 ± 0.0
20 Adenoma 0.0 0.0 0.0 0.0
Adenocarcinoma 0.0 0.0 0.0 0.0
Group 3 20 mg NNK i.p. Hyperplasia 0.2 ± 0.4 2.0 ± 1.0 1.2 ± 0.8 1.0 ± 0.7
+ 20 Adenoma 0.0 0.0 0.0 0.0
Quartz i.t. Adenocarcinoma 0.0 0.0 0.0 0.0
Group 4 10 mg NNK i.p. ×3 Hyperplasia 3.2 ± 2.6 3.2 ± 4.9 0.2 ± 0.4 0.8 ± 0.4
+ 20 Adenoma 0.0 0.0 0.0 0.0
Saline i.t. Adenocarcinoma 0.0 0.0 0.0 0.0
Group 5 10 mg NNK i.p. ×3 Hyperplasia 1.0 ± 0.7 3.2 ± 2.4 3.0 ± 1.6 0.8 ± 0.8
+ 20 Adenoma 0.0 0.0 0.0 0.0
Quartz i.t. Adenocarcinoma 0.0 0.0 0.0 0.0
Group 6 DHPN Hyperplasia 7.6 ± 4.0 17.0 ± 7.1 23.8 ± 7.3 26.4 ± 4.4
+ 20 Adenoma  1.2 ± 1.3 1.6 ± 2.1 1.0 ± 0.7 1.8 ± 1.1
Saline i.t. Adenocarcinoma 0.0 0.0 0.0 0.4 ± 0.5
Group 7 DHPN  Hyperplasia 6.8 ± 2.2 14.3 ± 2.2 19.8 ± 4.0 17.4 ± 4.0
+ 20 Adenoma  0.8 ± 0.8 0.8 ± 0.5 0.8 ± 1.3 2.0 ± 1.4
Quartz i.t. Adenocarcinoma 0.0 0.0 0.0 0.4 ± 0.5
*Effective number of rats: 20 rats were employed in each group, and subgroups of 5 rats each were assessed in weeks 12, 16, 23 and 30.
There is no significant difference between group 2 and 3, 4 and 5 or 6 and 7.74 Carcinogenic Bioassay of Nanoparticles
(10 mg NNK and quartz i.t. group), 297.9 ± 14.6, in week 23.
There were no significant intergroup differences in body
weight in the other groups.  The absolute and relative
weights of the lungs treated with quartz (groups 3, 5 and 7)
were increased significantly compared with the control
groups (groups 2, 4 and 6, respectively; data not shown). 
In regard to macroscopic findings, white spots were
seen on the surfaces of the lungs in the quartz i.t. groups.
White nodules were observed in groups 6 and 7 (DHPN
groups) in week 12, and these nodules grew sequentially
thereafter.  In the NNK and DHPN groups (groups 2–7),
there were no differences in nodule appearance with or
without quartz i.t. 
In regard to histopathological changes in the lungs,
hyperplastic lesions with mild inflammatory changes were
observed in groups 2–5 (NNK i.p. groups) at week 12, but
the hyperplastic lesions then decreased with time.  After
week 23, large granular lymphocytic lymphomas (LGL
lymphomas) were found around the trachea were apparent in
all rats treated with NNK i.p. (groups 2–5; Fig. 3).  The data
for the numbers of lung lesions in the various groups are
summarized in Table 1.  The NNK IP groups (groups 2–5)
did not demonstrate obvious development of epithelial
tumors in the lungs despite the inflammatory changes caused
by quartz.  In the DHPN groups (groups 6 and 7), lung
tumors and many hyperplasias were observed that increased
in number and size with time.  In the quartz i.t. groups
(groups 1, 3, 5 and 7), severe inflammatory changes with
neutrophil infiltration, histiocyte infiltration, pulmonary
edema and granuloma formation were observed at weeks 12,
16 and 23.  At week 30, they were somewhat reduced.  The
treatment with quartz i.t. did not influence the lung tumor
development in this experiment.  The livers and kidneys did
not demonstrate any significant histopathological alteration
in any group.
Experiment 2
No symptoms of dyspnea were observed after i.t.
treatment, and the general conditions of the rats in all the
groups did not change remarkably during the experimental
period. 
The final data for the body and organ weights in week
30 are shown in Table 2.  The absolute and relative liver
weights in group 2 (DHPN and CuO micro i.t.) were
decreased significantly compared with group 6 (DHPN
control group), while the absolute liver weights in group 1
(DHPN and quartz i.t.) were increased.  The body, lung and
kidney weights indicated no significant intergroup
differences. 
In regard to macroscopical findings, nodules in the
lungs were observed in the DHPN groups 1–6, but there was
no intergroup variation in number or area.  In the DHPN
untreated groups (groups 7–12), quartz i.t. (group 7) caused
some white spots on the surface of the lungs, while CuO
micro or nano i.t. (groups 8 and 9) induced mild nodulated
changes.  However, no lung lesions were found with TiO2
micro or nano i.t. (groups 10 and 11).
In regard to histopathological assessment, all the DHPN
groups (groups 1–6) contained hyperplasias, adenomas and
adenocarcinomas in the lungs (Fig. 4).  In the DHPN
untreated groups (Fig. 5), quartz i.t. (group 7) and, to a lesser
extent, CuO micro i.t. (group 8) caused granulomas.  CuO
nano i.t. (group 9) induced a milder inflammatory change.
Both TiO2 micro i.t. (group 10) and TiO2 nano i.t. (group 11)
were not associated with any appreciable inflammatory
change.  The data for histopathological lesions in the DHPN
groups (groups 1–6) are summarized in Tables 3 (the number
of lesions per cm2 in a histopathological sections) and 4 (%
areas).  There were no significant intergroup differences in
the numbers and areas of hyperplasias, adenomas and
adenocarcinomas.
Discussion and Conclusions
In experiment 1 of the present study, DHPN was found
to be more effective for induction of lung lesions than NNK,
Table 2. Body and Organ Weights of the Rats (Experiment 2)
No. of Lung Liver
Groups Treatment Instilled particles rats Body weight (g) Absolute (g) Relative (%) Absolute (g) Relative (%)
1 DHPN Quartz 15 321.0 ± 14.2 1.43 ± 0.12 0.44 ± 0.07 7.88 ± 0.46 2.45 ± 0.07a
2 DHPN CuO micro 15 321.0 ± 14.6 1.32 ± 0.11 0.41 ± 0.08 7.73 ± 0.44a 2.41 ± 0.08a
3 DHPN CuO nano 15 334.5 ± 26.4 1.56 ± 0.43 0.47 ± 0.15 8.42 ± 0.71 2.52 ± 0.09
4D H P N T i O 2 micro 15 340.9 ± 12.9 1.43 ± 0.05 0.42 ± 0.02 8.70 ± 0.41 2.55 ± 0.09
5D H P N T i O 2 nano 15 334.2 ± 16.7 1.45 ± 0.13 0.43 ± 0.04 8.58 ± 0.46 2.57 ± 0.10
6 DHPN Untreated 15 329.5 ± 22.2 1.44 ± 0.11 0.44 ± 0.03 8.45 ± 0.62 2.56 ± 0.08
7 Untreated Quartz 5 323.4 ± 19.1 1.36 ± 0.09 0.42 ± 0.01 8.22 ± 0.64 2.54 ± 0.09
8 Untreated CuO micro 5 325.7 ± 12.3 1.18 ± 0.12 0.36 ± 0.03 8.43 ± 0.61 2.59 ± 0.11
9 Untreated CuO nano 5 349.0 ± 31.8 1.37 ± 0.07 0.39 ± 0.02 9.10 ± 1.07 2.60 ± 0.13
10 Untreated TiO2 micro 5 350.7 ± 19.3 1.36 ± 0.08 0.39 ± 0.02 9.15 ± 0.77 2.61 ± 0.08
11 Untreated TiO2 nano 5 334.4 ± 15.4 1.34 ± 0.08 0.40 ± 0.02 8.38 ± 0.48 2.51 ± 0.05
12 Untreated Untreated 5 347.8 ± 15.5 1.37 ± 0.18 0.39 ± 0.04 9.17 ± 0.78 2.63 ± 0.14
a P<0.05 vs. DHPN control group (Group 6).Yokohira, Hashimoto, Yamakawa et al. 75
Fig. 3. Histopathological appearance of a large granular lymphocytic lymphoma (LGL lymphoma) in group 2 (20 mg NNK i.p. group) in
experiment 1.  A, magnification 12.5×; B, magnification 400×.
Fig. 4. Histopathological findings for the DHPN groups (groups 1–6) in experiment 2.  A, group 1 (quartz); B, group 6 (DHPN control),
adenocarcinoma indicated by the arrow; C, group 2 (CuO micro), hyperplasia indicated by the arrow; D, group 3 (CuO nano); E, group 4
(TiO2 micro), adenoma indicated by the arrow; F, group 5 (TiO2 nano).  The magnification in A–F is 12.5×.76 Carcinogenic Bioassay of Nanoparticles
the latter causing a 100% incidence of LGL lymphomas.
The LGL lymphoma may be observed as a spontaneous
neoplastic lesion in Fischer rats15; however Chung, et al.
reported that 1.5 mg/kg body weight NNK administered by
subcutaneous injection 3 times weekly for 21 weeks induces
a 36% incidence in F344 rats11.  In the DHPN groups (groups
6 and 7), lung hyperplasia, adenoma and adenocarcinoma
increased sequentially, but quartz had no effect on their
development.  At an early stage of the experiment, severe
inflammatory changes, especially neutrophil infiltration,
were observed in the acute phase that became milder with
time.  Based on the results of experiment 1, DHPN,
employed as a lung carcinogen, and evaluation at week 30
were concluded to be most appropriate for our purposes.
The results of experiment 2 showed that the numbers
and areas of neoplastic lesions induced by DHPN exhibited
no significant intergroup differences in groups 1–6.
However, in groups 3 and 5, the CuO or TiO2 nanoparticle
i.t. groups, the numbers and areas of neoplastic lesions
tended to increase compared with the data for microparticles
(groups 2 and 4).  Copper undergoes redox-cycling reactions
and produces reactive oxygen species17, though it has an
important role in the biological systems of various
metalloenzymes18,19.  Abe et al. reported about the
carcinogenic risk of copper gluconate, a copper-containing
compound, using a rat medium-term multi-organ
carcinogenicity bioassay model20.  Their report showed that
copper gluconate admixed in a diet at a concentration of
300–6000 ppm might pose carcinogenic risks for the liver
and forestomach at high dose levels.  TiO2 has been
Fig. 5. Histopathological findings for the DHPN untreated groups (groups 7–12) in experiment 2.  A, group 7 (quartz), granuloma indicated by
the arrow; B, group 12 (untreated); C, group 8 (CuO micro); D, group 9 (CuO nano); E, group 10 (TiO2 micro); F, group 11 (TiO2 nano).
The magnification is A–F is 12.5×.Yokohira, Hashimoto, Yamakawa et al. 77
classified as belonging to Group 2B (possibly carcinogenic
to humans) in an International Agency for Research on
Cancer (IARC) publication21.  It has also been reported that
TiO2 has carcinogenic potential22 and causes formation of
DNA adducts23.  On the other hand, it has also been reported
that TiO2 should not exert carcinogenic effects on the human
lung based on an overview epidemiology and toxicology
studies in mice, rats and hamsters24.
In general, nanoparticles are likely to exert a greater
impact because of the areas and characters of their
surfaces25.  The causes of the lack of clear effects in
experiment 2 might be related to the low doses or
frequencies of instillation used.  Intratracheal administration
of nanoparticles induces severe inflammatory changes in the
acute phase in the rat lung at high doses5, but given
chronically, the nanoparticles may be eliminated easily and
may induce only mild inflammatory changes.  It is well
known that nanoparticles spread from the primary target-
organ to other organs.  For example, in an oral
administration study in mice, nanoparticles of titanium
dioxide were found to be retained in many organs, such as
the liver, spleen, kidneys and lung tissues, after uptake
through the gastrointestinal tract26.  This spreading ability to
other organs of nanoparticles may indicate that the
nanoparticle is cleared from the primary organ, like the
lungs, earlier than microparticles.  However there are no
reports supporting this hypothesis, and further
experimentation is needed to validate the evidence.
In conclusion, there were no significant intergroup
differences in the neoplastic lesions induced by DHPN with
nanoparticles of CuO or TiO2 by i.t. despite a tendency for
increase compared with the microparticle i.t. groups.
However, this carcinogenic bioassay with DHPN appears
useful for detection of the modified effects of instilled
particles.  Assessment of the harmful effects of nanoparticles
is an important priority and should be pursued in more
investigations, such as with intraperitoneal application of
multiwall carbon nanotubes, which have been observed
induce mesotheliomas in the p53+/- mouse27.
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